Voyager Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
01 nov. 2022 07h30 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation...
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 oct. 2022 16h01 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation...
Voyager Therapeutics Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families
11 oct. 2022 07h00 HE
|
Voyager Therapeutics, Inc.
- Data presented at European Society of Gene & Cell Therapy (ESGCT) Congress 2022 - - Receptor findings support potential for human translation of Voyager’s capsids and may help overcome barriers...
Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target
04 oct. 2022 07h00 HE
|
Voyager Therapeutics, Inc.
Option exercise triggers $10 million payment to Voyager, further validating the potential of the TRACER capsid platform Voyager eligible for up to $290 million in associated development, regulatory,...
Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy
03 oct. 2022 07h00 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation...
Voyager Therapeutics to Participate in Upcoming Investor Conferences
27 sept. 2022 07h00 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation...
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22 sept. 2022 16h01 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation...
Voyager Therapeutics Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs
07 sept. 2022 07h30 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation...
Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results
04 août 2022 16h01 HE
|
Voyager Therapeutics, Inc.
Pipeline prioritizes tau antibody for Alzheimer's disease and gene therapies for GBA1 Parkinson's disease and SOD1 ALS, each program employing efficient paths to human proof of biology Targeting...
Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models
03 août 2022 11h30 HE
|
Voyager Therapeutics, Inc.
Novel passive antibodies bind to paired helical filamentous tau and inhibit propagation of pathological tau Vectorized antibody demonstrates durable CNS expression more than six months post-dose ...